Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1

Summary

The primary purpose of the study is to understand the effectiveness, safety, and tolerability of encaleret when compared to standard of care (SoC) treatment in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).

Timeline

Start

2023-01-06

Primary completion

2025-08-22

Completion

2029-08

Outcome

Met primary endpoint

release “CALIBRATE, the Phase 3 clinical trial of encaleret in ADH1, successfully achieved all pre-specified primary and key secondary efficacy endpoints” bridgebio.com ↗

Drugs

Indications